CompletedPhase 3

Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer

United States49 participantsStarted 2023-06-06

Plain-language summary

This phase III trial compares the effect of methylene blue mouthwash to standard of care mouthwash for the treatment of oral mucositis pain in patients with cancer. Using methlylene blue mouthwash may improve oral pain in patients with oral mucositis related to cancer and/or cancer treatments compared to usual standard of care.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Active cancer diagnosis * Admitted to the inpatient setting * Pain related to oral mucositis * Experiencing oropharyngeal pain * Able to provide informed consent Exclusion Criteria: * Pediatric age (under 18 years old) * Pregnant or nursing women * Any contraindication to methylene blue including severe hypersensitivity to methylene blue and patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of hemolytic anemia

What they're measuring

Change in oral pain

Timeframe: Baseline, 3 days

Trial details

NCT IDNCT05878405

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-06

View on ClinicalTrials.gov More Hematopoietic and Lymphoid System Neoplasm trials